196 related articles for article (PubMed ID: 38613897)
61. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway.
Wang Z; Wang N; Li W; Liu P; Chen Q; Situ H; Zhong S; Guo L; Lin Y; Shen J; Chen J
Carcinogenesis; 2014 Oct; 35(10):2346-56. PubMed ID: 25085904
[TBL] [Abstract][Full Text] [Related]
62. Challenging drug resistance in cancer therapy--review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9th and 10th, 1997.
Lehne G; Elonen E; Baekelandt M; Skovsgaard T; Peterson C
Acta Oncol; 1998; 37(5):431-9. PubMed ID: 9831371
[TBL] [Abstract][Full Text] [Related]
63. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
[TBL] [Abstract][Full Text] [Related]
64. ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance.
Fan J; To KKW; Chen ZS; Fu L
Drug Resist Updat; 2023 Jan; 66():100905. PubMed ID: 36463807
[TBL] [Abstract][Full Text] [Related]
65. Revisiting the ABCs of multidrug resistance in cancer chemotherapy.
Tiwari AK; Sodani K; Dai CL; Ashby CR; Chen ZS
Curr Pharm Biotechnol; 2011 Apr; 12(4):570-94. PubMed ID: 21118094
[TBL] [Abstract][Full Text] [Related]
66. The Role of the Hedgehog Pathway in Chemoresistance of Gastrointestinal Cancers.
Liang Y; Yang L; Xie J
Cells; 2021 Aug; 10(8):. PubMed ID: 34440799
[TBL] [Abstract][Full Text] [Related]
67. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
Yu M; Ocana A; Tannock IF
Cancer Metastasis Rev; 2013 Jun; 32(1-2):211-27. PubMed ID: 23093326
[TBL] [Abstract][Full Text] [Related]
68. Find new channel for overcoming chemoresistance in cancers: Role of stem cells-derived exosomal microRNAs.
Hussein GM; Mohammed SM; Faris M; Mohammed A; Kadhim MJ; Awadh SA; Ajam WH; Jalil AT
Int J Biol Macromol; 2022 Oct; 219():530-537. PubMed ID: 35948201
[TBL] [Abstract][Full Text] [Related]
69. Cancer Stem Cells and Targeting Strategies.
Barbato L; Bocchetti M; Di Biase A; Regad T
Cells; 2019 Aug; 8(8):. PubMed ID: 31426611
[TBL] [Abstract][Full Text] [Related]
70. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
[TBL] [Abstract][Full Text] [Related]
71. Therapy-induced chemoexosomes: Sinister small extracellular vesicles that support tumor survival and progression.
Bandari SK; Tripathi K; Rangarajan S; Sanderson RD
Cancer Lett; 2020 Nov; 493():113-119. PubMed ID: 32858103
[TBL] [Abstract][Full Text] [Related]
72. Pleiotropic Roles of ABC Transporters in Breast Cancer.
He J; Fortunati E; Liu DX; Li Y
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33801148
[TBL] [Abstract][Full Text] [Related]
73. Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.
Yakisich JS; Venkatadri R; Azad N; Iyer AKV
J Cell Physiol; 2017 Aug; 232(8):2033-2043. PubMed ID: 27504932
[TBL] [Abstract][Full Text] [Related]
74. Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance.
Shafi S; Khan S; Hoda F; Fayaz F; Singh A; Khan MA; Ali R; Pottoo FH; Tariq S; Najmi AK
Curr Drug Metab; 2020; 21(3):199-210. PubMed ID: 32124694
[TBL] [Abstract][Full Text] [Related]
75. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
Modok S; Mellor HR; Callaghan R
Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355
[TBL] [Abstract][Full Text] [Related]
76. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.
McIntosh K; Balch C; Tiwari AK
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):633-44. PubMed ID: 27116192
[TBL] [Abstract][Full Text] [Related]
77. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance.
Giddings EL; Champagne DP; Wu MH; Laffin JM; Thornton TM; Valenca-Pereira F; Culp-Hill R; Fortner KA; Romero N; East J; Cao P; Arias-Pulido H; Sidhu KS; Silverstrim B; Kam Y; Kelley S; Pereira M; Bates SE; Bunn JY; Fiering SN; Matthews DE; Robey RW; Stich D; D'Alessandro A; Rincon M
Nat Commun; 2021 May; 12(1):2804. PubMed ID: 33990571
[TBL] [Abstract][Full Text] [Related]
78. Aberrant protein glycosylation in cancer: implications in targeted therapy.
Rodrigues JG; Duarte HO; Reis CA; Gomes J
Biochem Soc Trans; 2021 Apr; 49(2):843-854. PubMed ID: 33704376
[TBL] [Abstract][Full Text] [Related]
79. Ceramide synthases in cancer therapy and chemoresistance.
Brachtendorf S; El-Hindi K; Grösch S
Prog Lipid Res; 2019 Apr; 74():160-185. PubMed ID: 30953657
[TBL] [Abstract][Full Text] [Related]
80. Novel nanomedicines to overcome cancer multidrug resistance.
Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
